Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.49 |
| ▸ | NPC1 | O15118 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.49 |
| ▸ | RELA | Q04206 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17730336 | 0.87 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL19449406 | 0.80 | GBA1 (0.48) | RAB9AMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23901591 | 0.79 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL24230362 | 0.75 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL17730363 | 0.74 | F2 (0.47) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL19554033 | 0.73 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL19438384 | 0.73 | ALDH1A1 (0.36) | KMT2AMEN1USP2ALDH1A1KDM4E | |
| SCHEMBL19578974 | 0.71 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL19579271 | 0.71 | ADRA1A (0.41) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22472782 | 0.70 | APOBEC3A (0.45) | RAB9ANPC1SMN1; SMN2TP53NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | RAB9A 1395/4885NPC1 823/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.